clinical trials as topic

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
Kevin Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K Felber, Cody J Peer, William D Figg, E Lake Potter, Mario Roederer, Douglas G McNeel, John A Thompson, Sumati Gupta, Rom Leidner, Andrea Wang-Gillam, Nehal S Parikh, Debby Long, Sema Kurtulus, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender, George N Pavlakis

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003388; DOI: 10.1136/jitc-2021-003388
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report
Angelo Dipasquale, Pasquale Persico, Elena Lorenzi, Daoud Rahal, Armando Santoro, Matteo Simonelli

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001870; DOI: 10.1136/jitc-2020-001870
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
Adrianne L Jenner, Tyler Cassidy, Katia Belaid, Marie-Claude Bourgeois-Daigneault, Morgan Craig

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001387; DOI: 10.1136/jitc-2020-001387
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E Bauman, Rhonda L Bitting, Alexander Starodub, Antonio Jimeno, David A Reardon, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Deepa S Subramaniam, Jeanny B Aragon-Ching, Thomas R Hawthorne, Tracey Rawls, Michael Yellin, Tibor Keler

Journal for ImmunoTherapy of Cancer Aug 2022, 10 (8) e005147; DOI: 10.1136/jitc-2022-005147
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Leisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L Disis, Margaret E Gatti-Mays, Alice Y Ho, Kevin Kalinsky, Heather L McArthur, Elizabeth A Mittendorf, Rita Nanda, David B Page, Hope S Rugo, Krista M Rubin, Hatem Soliman, Patricia A Spears, Sara M Tolaney, Jennifer K Litton

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002597; DOI: 10.1136/jitc-2021-002597
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
Russell K Pachynski, Chihiro Morishima, Russell Szmulewitz, Lauren Harshman, Leonard Appleman, Paul Monk, Rhonda L Bitting, Omer Kucuk, Frederick Millard, John D Seigne, Steven P Fling, Holden T Maecker, Caroline Duault, Nirasha Ramchurren, Bruce Hess, Leonard D’Amico, Andreanne Lacroix, Judith C Kaiser, Michel Morre, Anne Grégoire, Martin Cheever, Evan Y Yu, Lawrence Fong

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002903; DOI: 10.1136/jitc-2021-002903
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
Troels Holz Borch, Katja Harbst, Aynal Haque Rana, Rikke Andersen, Evelina Martinenaite, Per Kongsted, Magnus Pedersen, Morten Nielsen, Julie Westerlin Kjeldsen, Anders Handrup Kverneland, Martin Lauss, Lisbet Rosenkrantz Hölmich, Helle Hendel, Özcan Met, Göran Jönsson, Marco Donia, Inge Marie Svane

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002703; DOI: 10.1136/jitc-2021-002703
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Aaron C Tan, Stephen J Bagley, Patrick Y Wen, Michael Lim, Michael Platten, Howard Colman, David M Ashley, Wolfgang Wick, Susan M Chang, Evanthia Galanis, Alireza Mansouri, Simon Khagi, Minesh P Mehta, Amy B Heimberger, Vinay K Puduvalli, David A Reardon, Solmaz Sahebjam, John Simes, Scott J Antonia, Don Berry, Mustafa Khasraw

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002459; DOI: 10.1136/jitc-2021-002459
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Amanda C Guidon, Leeann B Burton, Bart K Chwalisz, James Hillis, Teilo H Schaller, Anthony A Amato, Allison Betof Warner, Priscilla K Brastianos, Tracey A Cho, Stacey L Clardy, Justine V Cohen, Jorg Dietrich, Michael Dougan, Christopher T Doughty, Divyanshu Dubey, Jeffrey M Gelfand, Jeffrey T Guptill, Douglas B Johnson, Vern C Juel, Robert Kadish, Noah Kolb, Nicole R LeBoeuf, Jenny Linnoila, Andrew L Mammen, Maria Martinez-Lage, Meghan J Mooradian, Jarushka Naidoo, Tomas G Neilan, David A Reardon, Krista M Rubin, Bianca D Santomasso, Ryan J Sullivan, Nancy Wang, Karin Woodman, Leyre Zubiri, William C Louv, Kerry L Reynolds

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002890; DOI: 10.1136/jitc-2021-002890
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
Sarina A Piha-Paul, Ravit Geva, Tira J Tan, Darren WT Lim, Cinta Hierro, Toshikiko Doi, Osama Rahma, Alexander Lesokhin, Jason John Luke, Javier Otero, Lisa Nardi, Angad Singh, Alexandros Xyrafas, Xinhui Chen, Jennifer Mataraza, Philippe L Bedard

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002863; DOI: 10.1136/jitc-2021-002863

Main menu

clinical trials as topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

clinical trials as topic

Pages